Resources

Development of an end-to-end Quantitative Model-Informed Drug Development (MIDD) ECOSYSTEM

Using Read-Across to build Physiologically-Based Kinetic models: Part 2. Case studies for atenolol and flumioxazin

Using read-across to build physiologically-based kinetic models: Part 1. Development of a KNIME workflow to assist analogue selection for PBK modelling

Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment

Studying metabolism with multiorgan chips: new tools for diseasemodelling, pharmacokinetics and pharmacodynamics

Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans

Local depletion of large molecule drugs due to target binding in tissue interstitial space

Quantitative adverse outcome pathway (qAOP) models for toxicityprediction

Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes PB-QSP Disease Platform